Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Rhea-AI Summary

Takeda has committed JPY4.6 billion (approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners, aiming to improve health systems in low and middle-income countries. This initiative is expected to impact 27 million people across 93 countries by 2030. The new partnerships will focus on:

1. Expanding vaccine access through pharmacy-based immunization in Africa
2. Integrating community-driven healthcare in rural South Africa
3. Increasing care access for women and girls in conflict-affected areas
4. Building skilled health workforces in African countries
5. Strengthening national health systems for disease outbreak response

These partnerships were selected by over 22,000 Takeda employees worldwide, demonstrating the company's commitment to collaborative global corporate giving. Since 2016, Takeda's Global CSR Program has reached 17.8 million direct beneficiaries in 93 countries, contributing to various aspects of health system strengthening.

Positive

• Commitment of JPY4.6 billion (approx. USD 32 million) to five new Global CSR partners
• Expected to impact 27 million people across 93 countries by 2030
• Total contributions from Takeda's Global CSR Program reach JPY 28.8 billion (approx. USD 199.1 million)
• Program has reached 17.8 million direct beneficiaries since 2016
• Partnerships focus on improving health systems in low and middle-income countries

Negative

• None.

Financial Analyst

Takeda's commitment of $32 million to five new Global CSR partnerships is a significant investment in corporate social responsibility. While this demonstrates Takeda's commitment to improving global health systems, the financial impact on the company is relatively minor given its size. The total CSR program contributions of $199.1 million since 2016 represent a small fraction of Takeda's annual revenue, which was approximately $30 billion in 2022.

From an investor's perspective, this initiative may enhance Takeda's reputation and potentially contribute to long-term brand value. However, the immediate financial impact on the company's stock performance is likely to be minimal. The focus on health system resilience in low and middle-income countries aligns with Takeda's core business in pharmaceuticals and could potentially open new markets in the future, but this would be a long-term consideration.

Market Research Analyst

Takeda's expanded CSR program, reaching 93 countries and potentially 27 million people by 2030, showcases a strategic approach to market development. By strengthening health systems in emerging markets, Takeda is laying groundwork for future business expansion. The focus on vaccine access, community-driven healthcare and health workforce development aligns with global health trends and could position Takeda favorably in these markets.

The employee involvement in partner selection (22,000 employees across 80 countries) indicates strong internal engagement, which can positively impact company culture and employee retention. This approach may also enhance Takeda's ability to attract top talent, particularly among younger generations who prioritize corporate social responsibility.

While the immediate market impact may be , this initiative could contribute to Takeda's long-term growth strategy in emerging markets, potentially translating to increased shareholder value over time.

Medical Research Analyst

Takeda's partnerships focus on critical areas of global health, including vaccine access, maternal and neonatal care and outbreak response. The collaboration with PSI to expand pharmacy-based immunization in Africa is particularly noteworthy, as it addresses a key challenge in vaccine distribution. This approach could serve as a model for improving vaccination rates in other regions.

The partnership with Seed Global Health to develop academic programs in OB/GYN and neonatal emergency care addresses a important need in maternal and child health. By graduating 5,900 qualified health professionals, this initiative could significantly impact health outcomes in the target countries.

VillageReach's focus on strengthening laboratory systems for rapid diagnosis and outbreak response is timely, given the recent global experiences with pandemics. This initiative could contribute valuable data and best practices for global health security efforts.

While these programs may not directly impact Takeda's drug development pipeline, they demonstrate the company's commitment to addressing global health challenges and could inform future research priorities.

• More Than 22,000 Takeda Employees Selected the FY2024 New Partners: Population Services International, Bulungula Incubator, Reach Out Cameroon, Seed Global Health and VillageReach
• Takeda’s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 28.8 Billion (Approx. USD 199.1 million) Across 34 Diverse Partnerships Worldwide and extend our reach to an additional 2 million direct beneficiaries
• Takeda’s Global CSR Program Expects to Reach 27 Million People in 93 Countries by 2030

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce, and increasing local knowledge and capacity to improve equitable and sustainable healthcare access and delivery.

By 2030, these new collaborations are anticipated to extend Takeda’s impact to 27 million people across 93 countries, raising the total contributions from Takeda’s Global CSR Program to over JPY 28.8 billion (Approx. USD 199.1 million) across 34 significant partnerships since it began in 2016. The five new partners were selected by more than 22,000 Takeda employees across 80 countries and regions through a company-wide vote, highlighting the company’s commitment to a collaborative and inclusive approach in its global corporate giving initiative.

“Since our founding in 1781, Takeda has put patients, people and society at the center of its business decisions. We are committed to being a respected partner, making a long-term contribution to society to address health challenges worldwide. Our Global CSR Program has served as a strong demonstration of this commitment since 2016.” said Takako Ohyabu, chief global corporate affairs and sustainability officer at Takeda. “I’m particularly proud of each of our new partners’ thoughtful commitment to equity, scalability and sustainability as cornerstones of health systems resiliency. These long-term partnerships will not only deliver tangible impact, but they will also share invaluable lessons, creating a ripple effect of innovation and improved health outcomes for people worldwide, especially for vulnerable populations in remote and conflict settings.”

Takeda’s commitments to these new partners in FY2024 include:

• JPY 1,007 million (Approx. USD 7.0 million) to Population Services International (PSI) to expand vaccine access through pharmacy-based immunization across Ethiopia, Kenya and Nigeria, linking pharmacies to national vaccination programs, creating new service points within health systems and reducing the burden on public clinics, ultimately creating a blueprint to scale immunization access across Africa.
• JPY 310 million (Approx. USD 2.1 million) to Bulungula Incubator to integrate a community-driven, holistic healthcare approach with the national health system in South Africa’s remote Xhorha Mouth Administrative Area, demonstrating a replicable approach to universal healthcare in rural areas, empowering community health workers, and integrating healthcare across local schools, sports events and community radio.
• JPY 1,169 million (Approx. USD 8.1 million) to Reach Out Cameroon to increase access to appropriate care and psychosocial support for women and girls in extremely hard-to-reach communities experiencing long-term conflict in Cameroon, Democratic Republic of Congo and Nigeria by training health workers, supply chain managers and youth champions, and increasing the capacity of 270 poorly equipped health facilities in highly populated communities to offer quality services, supplies and information.
• JPY 895 million (Approx. USD 6.2 million) to Seed Global Health to support Malawi, Sierra Leone, Uganda and Zambia in building a skilled health workforce to support their national health goals including launching new academic programs in OB/GYN and neonatal emergency care, establishing three locally led centers of excellence for maternal and neonatal health service training and delivery and graduating 5,900 qualified health professionals ready to serve their communities.
• JPY 1,259 million (Approx. USD 8.7 million) to VillageReach to support Democratic Republic of Congo, Guinea, Malawi, Tanzania and Uganda in strengthening the capacity of their national health systems to rapidly and reliably transport patient samples to laboratories for diagnosis and promptly respond to outbreaks, as well as create an integrated solution for all outbreak-prone diseases to contain them faster. As a result, countries will be able to detect diseases early, save lives and reduce the burden on fragile health systems during disruptions.

The new partners shared:

• “Vaccines save people’s lives, and amidst global decreases in routine immunizations we see the potential to mobilize pharmacies to provide vaccines – all at scale,” said Karl Hofmann, CEO and president, PSI. “This partnership will support health systems to increase vaccination rates, equip people to take charge of their health, and accelerate our collective progress toward Universal Health Coverage.”
• “We are honored to partner with Takeda to significantly enhance healthcare access and outcomes in remote rural communities, ensuring sustainable, community-driven health solutions,” said Réjane Woodroffe, director, Bulungula Incubator. “By enclosing the circle of compassion and care, we are committed to including those most often left behind. Together, we aim to create resilient communities where every individual has the opportunity to thrive.”
• “At a time when the world is facing severe challenges from humanitarian emergencies, especially conflict-driven emergencies, access to quality care is the right of every woman and girl,” said Esther Omam Njomo, executive director, Reach Out Cameroon. “Our partnership with Takeda is a bold step towards improving that access for women and girls in conflict-affected communities in Cameroon, DR Congo and Nigeria.”
• “Takeda’s generous support allows Seed Global Health and our local partners to train more doctors, nurses, and midwives and provide them with the resources they need to deliver high quality care and save lives,” said Andrew Musoke, COO, Seed Global Health.
• “With a rise in emerging outbreaks, the need for responsive primary health care systems is more urgent than ever,” said Emily Bancroft, CEO and president, VillageReach. “This partnership with Takeda offers a timely opportunity to work with governments to bolster the infrastructure that allows them to detect and contain outbreaks quickly. By speeding up identification and diagnosis, we can enable swift response to extreme epidemics and save countless lives.”

Since its launch in 2016, Takeda’s Global CSR Program has reached more than 17.8 million direct beneficiaries in 93 countries and contributed to strengthening health systems including the following areas informed by WHO’s Health System Strengthening Building Blocks:

• Accelerating Service Delivery and Access to Essential Medicines: Improved accessibility, coverage and quality of service delivery (e.g., screening, referrals and follow ups) for more than 13.4 million people; provided essential health supplies to more than 28,000 people; empowered more than 4.1 million community members with targeted health education, including on nutrition, water, sanitation, hygiene, and sexual and reproductive health; and refurbished or built over 2,700 health facilities.
• Empowering the Health Workforce: Developed knowledge, skills, motivation and deployment of health workforce by providing training to more than 110,000 qualified health professionals and community health workers responsible for organizing and delivering health services, as well as those who do not deliver services directly but are essential to the performance of health systems, such as health supply chain managers and health information system administrators.
• Advancing Health Information Systems: Developed, enhanced, or implemented 276 digital solutions, platforms, or tools to support data-informed health planning and health decision-making.
• Strengthening Leadership and Governance: Developed or enhanced 420 strategic plans and policies linked to national and local needs and priorities to ensure local ownership while sustaining and scaling innovative solutions.

About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Exchange Rates
In this press release certain amounts presented in Japanese yen have been translated to US dollars solely for the convenience of the reader. Except where otherwise noted, these convenience translations have been made at an exchange rate of 1USD = 144.86 JPY, the Noon Buying Rate certified by the Federal Reserve Bank of New York on August 23, 2024. The rate and methodologies used for these convenience translations differ from the currency exchange rates and translation methodologies under IFRS used for the preparation of Takeda’s consolidated financial statements. These translations should not be construed as a representation that the relevant Japanese yen amounts could be converted into U.S. dollars at this or any other rate.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910318493/en/

Media Contacts:

media_relations@takeda.com

Source: Takeda Pharmaceutical Company Limited

FAQ

How much has Takeda (TAK) committed to its new Global CSR partnerships in 2024?

Takeda has committed JPY4.6 billion (approximately USD 32 million) to five new Global Corporate Social Responsibility (CSR) partnerships in 2024.

How many people does Takeda (TAK) expect to reach through its Global CSR Program by 2030?

Takeda expects its Global CSR Program to reach 27 million people across 93 countries by 2030.

What are the focus areas of Takeda's (TAK) new CSR partnerships announced in 2024?

The new partnerships focus on expanding vaccine access in Africa, integrating community-driven healthcare in rural South Africa, increasing care access for women and girls in conflict-affected areas, building skilled health workforces in African countries, and strengthening national health systems for disease outbreak response.

How many Takeda employees participated in selecting the new CSR partners for 2024?

More than 22,000 Takeda employees across 80 countries and regions participated in selecting the new CSR partners through a company-wide vote.

What is the total contribution of Takeda's (TAK) Global CSR Program since its inception in 2016?

Since 2016, Takeda's Global CSR Program has contributed over JPY 28.8 billion (approximately USD 199.1 million) across 34 significant partnerships.